Pharmaceutical R&D, Covidien, 385 Marshall Ave, Webster Groves, Missouri 63119, USA.
AAPS PharmSciTech. 2010 Sep;11(3):1466-75. doi: 10.1208/s12249-010-9520-y. Epub 2010 Sep 15.
The objective of the present research was to evaluate the physicochemical characteristics of berberine chloride and to assess the complexation of drug with 2-hydroxypropyl-β-cyclodextrin (HPβCD), a first step towards solution dosage form development. The parameters such as log P value were determined experimentally and compared with predicted values. The pH-dependent aqueous solubility and stability were investigated following standard protocols at 25°C and 37°C. Drug solubility enhancement was attempted utilizing both surfactants and cyclodextrins (CDs), and the drug/CD complexation was studied employing various techniques such as differential scanning calorimetry, Fourier transform infrared, nuclear magnetic resonance, and scanning electron microscopy. The experimental log P value suggested that the compound is fairly hydrophilic. Berberine chloride was found to be very stable up to 6 months at all pH and temperature conditions tested. Aqueous solubility of the drug was temperature dependent and exhibited highest solubility of 4.05 ± 0.09 mM in phosphate buffer (pH 7.0) at 25°C, demonstrating the effect of buffer salts on drug solubility. Decreased drug solubility was observed with increasing concentrations of ionic surfactants such as sodium lauryl sulfate and cetyl trimethyl ammonium bromide. Phase solubility studies demonstrated the formation of berberine chloride-HPβCD inclusion complex with 1:1 stoichiometry, and the aqueous solubility of the drug improved almost 4.5-fold in the presence of 20% HPβCD. The complexation efficiency values indicated that the drug has at least threefold greater affinity for hydroxypropyl-β-CD compared to randomly methylated-β-CD. The characterization techniques confirmed inclusion complex formation between berberine chloride and HPβCD and demonstrated the feasibility of developing an oral solution dosage form of the drug.
本研究的目的是评估盐酸小檗碱的理化特性,并评估药物与 2-羟丙基-β-环糊精(HPβCD)的络合情况,这是开发溶液剂型的第一步。通过实验确定了诸如 log P 值等参数,并与预测值进行了比较。根据标准方案,在 25°C 和 37°C 下研究了 pH 依赖性水溶解度和稳定性。尝试使用表面活性剂和环糊精(CDs)来提高药物溶解度,并使用差示扫描量热法、傅里叶变换红外光谱、核磁共振和扫描电子显微镜等各种技术研究药物/CD 络合情况。实验 log P 值表明该化合物具有相当的亲水性。盐酸小檗碱在所有测试的 pH 和温度条件下均非常稳定,可稳定长达 6 个月。药物的水溶解度随温度而变化,在 25°C 时磷酸盐缓冲液(pH 7.0)中的溶解度最高,为 4.05±0.09mM,表明缓冲盐对药物溶解度的影响。随着离子表面活性剂如十二烷基硫酸钠和十六烷基三甲基溴化铵浓度的增加,药物的溶解度降低。相溶解度研究表明,盐酸小檗碱-HPβCD 以 1:1 的化学计量比形成包合物,在 20% HPβCD 的存在下,药物的水溶解度提高了近 4.5 倍。络合效率值表明,与随机甲基化-β-CD 相比,药物对羟丙基-β-CD 的亲和力至少大三倍。表征技术证实了盐酸小檗碱和 HPβCD 之间形成了包合物,并证明了开发该药物口服溶液剂型的可行性。